AU2014221210A1 - The use of solid carrier particles to improve the processability of a pharmaceutical agent - Google Patents
The use of solid carrier particles to improve the processability of a pharmaceutical agentInfo
- Publication number
- AU2014221210A1 AU2014221210A1 AU2014221210A AU2014221210A AU2014221210A1 AU 2014221210 A1 AU2014221210 A1 AU 2014221210A1 AU 2014221210 A AU2014221210 A AU 2014221210A AU 2014221210 A AU2014221210 A AU 2014221210A AU 2014221210 A1 AU2014221210 A1 AU 2014221210A1
- Authority
- AU
- Australia
- Prior art keywords
- processability
- improve
- pharmaceutical agent
- carrier particles
- solid carrier
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000969 carrier Substances 0.000 title 1
- 239000002245 particle Substances 0.000 title 1
- 239000008177 pharmaceutical agent Substances 0.000 title 1
- 239000007787 solid Substances 0.000 title 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2014221210A AU2014221210C1 (en) | 2008-05-02 | 2014-09-03 | The use of solid carrier particles to improve the processability of a pharmaceutical agent |
| AU2016250470A AU2016250470A1 (en) | 2008-05-02 | 2016-10-28 | The use of solid carrier particles to improve the processability of a pharmaceutical agent |
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4993508P | 2008-05-02 | 2008-05-02 | |
| US61/049,935 | 2008-05-02 | ||
| US15065209P | 2009-02-06 | 2009-02-06 | |
| US15065509P | 2009-02-06 | 2009-02-06 | |
| US61/150,655 | 2009-02-06 | ||
| US61/150,652 | 2009-02-06 | ||
| PCT/US2009/042607 WO2009135179A2 (en) | 2008-05-02 | 2009-05-01 | The use of solid carrier particles to improve the processability of a pharmaceutical agent |
| AU2009242451A AU2009242451C1 (en) | 2008-05-02 | 2009-05-01 | The use of solid carrier particles to improve the processability of a pharmaceutical agent |
| AU2014221210A AU2014221210C1 (en) | 2008-05-02 | 2014-09-03 | The use of solid carrier particles to improve the processability of a pharmaceutical agent |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2009242451A Division AU2009242451C1 (en) | 2008-05-02 | 2009-05-01 | The use of solid carrier particles to improve the processability of a pharmaceutical agent |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2016250470A Division AU2016250470A1 (en) | 2008-05-02 | 2016-10-28 | The use of solid carrier particles to improve the processability of a pharmaceutical agent |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| AU2014221210A1 true AU2014221210A1 (en) | 2014-09-25 |
| AU2014221210B2 AU2014221210B2 (en) | 2016-08-18 |
| AU2014221210C1 AU2014221210C1 (en) | 2017-06-01 |
Family
ID=40809930
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2009242451A Active AU2009242451C1 (en) | 2008-05-02 | 2009-05-01 | The use of solid carrier particles to improve the processability of a pharmaceutical agent |
| AU2014221210A Active AU2014221210C1 (en) | 2008-05-02 | 2014-09-03 | The use of solid carrier particles to improve the processability of a pharmaceutical agent |
| AU2016250470A Abandoned AU2016250470A1 (en) | 2008-05-02 | 2016-10-28 | The use of solid carrier particles to improve the processability of a pharmaceutical agent |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2009242451A Active AU2009242451C1 (en) | 2008-05-02 | 2009-05-01 | The use of solid carrier particles to improve the processability of a pharmaceutical agent |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2016250470A Abandoned AU2016250470A1 (en) | 2008-05-02 | 2016-10-28 | The use of solid carrier particles to improve the processability of a pharmaceutical agent |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US10039718B2 (en) |
| EP (2) | EP3006032A1 (en) |
| JP (2) | JP5722213B2 (en) |
| KR (2) | KR101659971B1 (en) |
| CN (3) | CN102123700A (en) |
| AP (1) | AP3089A (en) |
| AU (3) | AU2009242451C1 (en) |
| BR (1) | BRPI0911871A8 (en) |
| CA (1) | CA2720856C (en) |
| CO (1) | CO6321225A2 (en) |
| CY (1) | CY1117067T1 (en) |
| DK (1) | DK2296633T3 (en) |
| EA (2) | EA022950B1 (en) |
| EC (1) | ECSP10010636A (en) |
| ES (1) | ES2553897T3 (en) |
| HK (2) | HK1153670A1 (en) |
| HR (1) | HRP20151357T1 (en) |
| HU (1) | HUE026380T2 (en) |
| IL (2) | IL208614A (en) |
| MX (2) | MX2010011963A (en) |
| NZ (1) | NZ588978A (en) |
| PL (1) | PL2296633T3 (en) |
| PT (1) | PT2296633E (en) |
| SG (2) | SG10201609006WA (en) |
| SI (1) | SI2296633T1 (en) |
| WO (1) | WO2009135179A2 (en) |
| ZA (1) | ZA201008007B (en) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2546378T3 (en) | 2006-07-07 | 2015-09-23 | Gilead Sciences, Inc. | Modulators of pharmacokinetic properties of therapeutic agents |
| EA019893B1 (en) * | 2007-02-23 | 2014-07-30 | Джилид Сайэнс, Инк. | Pharmaceutical composition and method for treating hiv infection |
| CN101743004A (en) * | 2007-06-29 | 2010-06-16 | 吉里德科学公司 | Therapeutic compositions and the use thereof |
| SG182229A1 (en) * | 2007-06-29 | 2012-07-30 | Gilead Sciences Inc | Therapeutic compositions and the use thereof |
| MX2010011963A (en) | 2008-05-02 | 2010-12-06 | Gilead Sciences Inc | The use of solid carrier particles to improve the processability of a pharmaceutical agent. |
| UA108738C2 (en) | 2009-04-03 | 2015-06-10 | METHOD OF PREPARATION OF CYTOCHROME INVENTOR P450 MONOOXYGENASES AND INTERMEDIATED INTERMEDIATES | |
| PL2640362T5 (en) | 2010-11-19 | 2022-05-02 | Gilead Sciences, Inc. | Therapeutic compositions comprising rilpivirin hcl and tenovofir disoproxil fumarate |
| JP2014513123A (en) * | 2011-05-02 | 2014-05-29 | ギリアード サイエンシーズ， インコーポレイテッド | Amorphous solid salt |
| KR102058097B1 (en) | 2011-07-07 | 2019-12-20 | 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 | Darunavir combination formulations |
| AR087546A1 (en) | 2011-08-16 | 2014-04-03 | Gilead Sciences Inc | TENOFOVIR ALAFENAMIDE HEMIFUMARATE |
| WO2013106732A1 (en) | 2012-01-12 | 2013-07-18 | Gilead Sciences, Inc. | Pharmaceutical compositions and methods for their preparation |
| SG10201509336RA (en) | 2012-02-03 | 2015-12-30 | Gilead Sciences Inc | Methods and intermediates for preparing pharmaceutical agents |
| WO2013130766A1 (en) | 2012-03-01 | 2013-09-06 | Gilead Sciences, Inc. | Spray dried formulations |
| BR112015006558A2 (en) * | 2012-10-23 | 2017-07-04 | Cipla Ltd | pharmaceutical composition, process for preparing a pharmaceutical composition, use of a pharmaceutical composition, and method for preventing or treating retrovirus diseases |
| JP2016504364A (en) * | 2012-12-26 | 2016-02-12 | アッシア・ケミカル・インダストリーズ・リミテッド | Cobicistat salt |
| DE102013205347A1 (en) | 2013-03-26 | 2014-10-02 | Hilti Aktiengesellschaft | An additive composition for amine curing agents, their use, and amine-curing agent composition containing them |
| CN103230403A (en) * | 2013-04-23 | 2013-08-07 | 苏州谷力生物科技有限公司 | Anti-HIV (Human Immunodeficiency Virus) combined drug tablet |
| US20170035911A1 (en) * | 2013-11-29 | 2017-02-09 | Mylan Laboratories Ltd. | Amorphous Cobicistat Solid Dispersion |
| WO2015145324A1 (en) | 2014-03-25 | 2015-10-01 | Mylan Laboratories Ltd | Process for the preparation of cobicistat |
| US20160145344A1 (en) * | 2014-10-20 | 2016-05-26 | University Of Southern California | Murine and human innate lymphoid cells and lung inflammation |
| US10166185B2 (en) * | 2015-06-09 | 2019-01-01 | J. Rettenmaier & Söhne Gmbh + Co Kg | Excipient and oral solid dosage forms for oily drugs |
| WO2016201119A1 (en) * | 2015-06-09 | 2016-12-15 | J. Rettenmaier & Söhne Gmbh + Co Kg | Excipient and oral solid dosage forms for oily drugs |
| TW201728582A (en) * | 2016-01-28 | 2017-08-16 | 基利科學股份有限公司 | Crystalline form |
| EP3496719B1 (en) | 2016-08-08 | 2023-06-14 | Hetero Labs Limited | A multi-class anti-retroviral composition |
| BR112019002132A2 (en) | 2016-08-08 | 2019-05-14 | Hetero Labs Limited | antiretroviral compositions |
| WO2020122242A1 (en) * | 2018-12-14 | 2020-06-18 | 富士フイルム株式会社 | Pharmaceutical composition and method for producing same |
| CN110251476B (en) * | 2019-08-01 | 2022-08-09 | 海思科制药(眉山)有限公司 | Emtricitabine tenofovir pharmaceutical composition |
| CN113425702B (en) * | 2021-06-25 | 2022-08-26 | 中国药科大学 | Preparation method, device and application of nanoparticles by applying microfluidic technology |
Family Cites Families (96)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3400197A (en) * | 1965-01-26 | 1968-09-03 | Robins Co Inc A H | Compressible sustained release pharmaceutical tablet lipid-colloidal silica gel matrix fragment granules |
| GB1241024A (en) | 1968-10-29 | 1971-07-28 | Boehringer Sohn Ingelheim | Pharmaceutical tablet base and a process for its manufacture |
| NL149711B (en) | 1970-06-15 | 1976-06-15 | Sumitomo Chemical Co | METHOD OF MANUFACTURING PILLS, AS WELL AS THE PILLS MANUFACTURED THEREFORE. |
| CH586568A5 (en) | 1972-04-10 | 1977-04-15 | Hoffmann La Roche | |
| DE2845326C2 (en) * | 1978-10-18 | 1985-05-23 | Beiersdorf Ag, 2000 Hamburg | Use of a specific microdisperse, amorphous, porous silica for the production of digoxin-containing tablets with a strongly accelerated release of active ingredient |
| US4603143A (en) * | 1983-05-02 | 1986-07-29 | Basf Corporation | Free-flowing, high density, fat soluble vitamin powders with improved stability |
| GB8413191D0 (en) | 1984-05-23 | 1984-06-27 | Beecham Group Plc | Pharmaceutical composition |
| FR2609958B1 (en) | 1987-01-27 | 1995-03-10 | Honda Motor Co Ltd | SUPPORT DEVICE FOR REAR WHEELS OF MOTORCYCLES |
| FR2631620B1 (en) | 1988-05-19 | 1990-07-27 | Rhone Poulenc Chimie | NOVEL PRECIPITATED ABSORBENT SILICA AND COMPOSITION BASED ON SAILOR |
| US5552558A (en) * | 1989-05-23 | 1996-09-03 | Abbott Laboratories | Retroviral protease inhibiting compounds |
| US5354866A (en) * | 1989-05-23 | 1994-10-11 | Abbott Laboratories | Retroviral protease inhibiting compounds |
| IE20010533A1 (en) | 1990-11-20 | 2003-03-05 | Abbott Lab | Intermediates for preparing retroviral protease inhibiting compounds |
| GB9109862D0 (en) | 1991-05-08 | 1991-07-03 | Beecham Lab Sa | Pharmaceutical formulations |
| ZA923640B (en) | 1991-05-21 | 1993-02-24 | Iaf Biochem Int | Processes for the diastereoselective synthesis of nucleosides |
| DK1302468T3 (en) | 1992-12-29 | 2009-03-02 | Abbott Lab | Methods and intermediates for the preparation of compounds that inhibit retroviral protease |
| GB9301192D0 (en) | 1993-06-09 | 1993-06-09 | Trott Francis W | Flower shaped mechanised table |
| WO1995005808A1 (en) * | 1993-08-24 | 1995-03-02 | Abbott Laboratories | Oil-based tableting method |
| US5559158A (en) * | 1993-10-01 | 1996-09-24 | Abbott Laboratories | Pharmaceutical composition |
| US5948438A (en) | 1995-01-09 | 1999-09-07 | Edward Mendell Co., Inc. | Pharmaceutical formulations having improved disintegration and/or absorptivity |
| US5585115A (en) | 1995-01-09 | 1996-12-17 | Edward H. Mendell Co., Inc. | Pharmaceutical excipient having improved compressability |
| GB9514464D0 (en) | 1995-07-14 | 1995-09-13 | Glaxo Lab Sa | Medicaments |
| JP4064476B2 (en) * | 1996-03-29 | 2008-03-19 | エラワン ファーマスーティカル リサーチ アンドラボラトリー カンパニー リミテッド | Spherical agglomerated starch with silicon dioxide |
| US6348216B1 (en) * | 1996-06-10 | 2002-02-19 | Knoll Pharmaceutical Company | Ibuprofen and narcotic analgesic compositions |
| US6361794B1 (en) * | 1996-06-12 | 2002-03-26 | Basf Corporation | Method of making ibuprofen and narcotic analgesic composition |
| US5922695A (en) | 1996-07-26 | 1999-07-13 | Gilead Sciences, Inc. | Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability |
| US5939090A (en) * | 1996-12-03 | 1999-08-17 | 3M Innovative Properties Company | Gel formulations for topical drug delivery |
| JP4494539B2 (en) * | 1997-02-28 | 2010-06-30 | ディーエスエム アイピー アセッツ ビー．ブイ． | Free-flowing dry particles |
| FR2767071B1 (en) | 1997-08-06 | 1999-09-10 | Rhodia Chimie Sa | COMPOSITION COMPRISING A LIQUID ABSORBED ON A PRECIPITATED SILICA BASE |
| JP4027535B2 (en) | 1998-05-26 | 2007-12-26 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | Powder containing fat-soluble drug |
| US6342249B1 (en) * | 1998-12-23 | 2002-01-29 | Alza Corporation | Controlled release liquid active agent formulation dosage forms |
| WO2003030868A1 (en) | 2001-10-09 | 2003-04-17 | Bristol-Myers Squibb Company | Flashmelt oral dosage formulation |
| CA2311734C (en) * | 2000-04-12 | 2011-03-08 | Bristol-Myers Squibb Company | Flash-melt oral dosage formulation |
| US20030035834A1 (en) * | 2000-05-26 | 2003-02-20 | Pawan Seth | Sustained release verapamil pharmaceutical composition free of food effect and a method for alleviating food effect in drug release |
| WO2002024167A1 (en) * | 2000-09-19 | 2002-03-28 | Daiichi Pharmaceutical Co., Ltd. | Medicinal composition |
| US7056951B2 (en) * | 2000-09-26 | 2006-06-06 | Mutual Pharmaceutical Co., Inc. | Stable solid dosage forms of amino acids and processes for producing same |
| US6524615B2 (en) * | 2001-02-21 | 2003-02-25 | Kos Pharmaceuticals, Incorporated | Controlled release pharmaceutical composition |
| DE10112651A1 (en) | 2001-03-16 | 2002-09-19 | Degussa | Inhomogeneous silicas as carrier material |
| MXPA03009391A (en) * | 2001-05-01 | 2004-01-29 | Pfizer Prod Inc | Method for manufacturing a low dose pharmaceutical composition having uniform drug distribution and potency. |
| HUP0400080A3 (en) | 2001-05-18 | 2004-10-28 | Lonza Ag | Method for the production of solid formulations of sodium 3-hydroxy-3-methylbutyrate |
| DE10126163A1 (en) * | 2001-05-30 | 2002-12-05 | Degussa | Solid, semi-solid or liquid pharmaceutical or cosmetic preparations, containing pyrogenic silicon dioxide of high tamped density as auxiliary to provide good flow properties |
| BR0210867A (en) * | 2001-07-06 | 2004-06-29 | Lifecycle Pharma As | A process for the preparation of a particulate material, methods for controlled agglomeration of a finely dispersed solid material, for improving the bioavailability of a therapeutic and / or prophylactically active substance, and for improving the shelf life of a pharmaceutical composition, articulated material, composition. pharmaceutical, use of a vehicle, pharmaceutical particulate matter, and use of magnesium aluminosilicate and / or magnesium aluminomethyl silicate |
| GB0123400D0 (en) * | 2001-09-28 | 2001-11-21 | Novartis Ag | Organic compounds |
| DE10153078A1 (en) * | 2001-10-30 | 2003-05-22 | Degussa | Use of granules based on pyrogenic silicon dioxide in pharmaceutical compositions |
| US7815936B2 (en) * | 2001-10-30 | 2010-10-19 | Evonik Degussa Gmbh | Use of granular materials based on pyrogenically produced silicon dioxide in pharmaceutical compositions |
| WO2003047551A1 (en) | 2001-11-29 | 2003-06-12 | Penwest Pharmaceutical Company | Agglomerated particles including an active agent coprocessed with silicified microcrystalline cellulose |
| US20030206978A1 (en) * | 2001-11-29 | 2003-11-06 | Bob Sherwood | Agglomerated particles including an active agent coprocessed with silicified microcrystalline cellulose |
| US6926906B2 (en) * | 2002-02-20 | 2005-08-09 | M./S. Strides, Inc. | Orally administrable pharmaceutical formulation |
| PA8576201A1 (en) * | 2002-07-10 | 2004-05-26 | Pfizer Prod Inc | PHARMACEUTICAL COMPOSITION THAT HAS A DISTRIBUTION AND UNIFORM POWER OF FARMACO |
| DE10250711A1 (en) * | 2002-10-31 | 2004-05-19 | Degussa Ag | Pharmaceutical and cosmetic preparations |
| JP3567162B1 (en) | 2002-11-20 | 2004-09-22 | 日本たばこ産業株式会社 | 4-oxoquinoline compounds and their use as HIV integrase inhibitors |
| EP4059923A1 (en) * | 2002-11-20 | 2022-09-21 | Japan Tobacco Inc. | 4-oxoquinoline compound and use thereof as hiv integrase inhibitor |
| US7189416B2 (en) * | 2002-11-23 | 2007-03-13 | Glykon Technologies Group, Llc | Method for stable and controlled delivery of (-)-hydroxycitric acid |
| AU2004206821C1 (en) | 2003-01-14 | 2009-10-01 | Gilead Sciences, Inc. | Compositions and methods for combination antiviral therapy |
| JP2006517929A (en) * | 2003-02-19 | 2006-08-03 | ハー・ルンドベック・アクチエゼルスカベット | Method for producing agglomerates using melt agglomeration |
| WO2004073689A1 (en) | 2003-02-19 | 2004-09-02 | Lifecycle Pharma A/S | Use of a silica or silica derivative as a sorption material |
| FR2851918B1 (en) * | 2003-03-06 | 2006-06-16 | IMPREGNATED POWDER ENHANCING BIOAVAILABILITY AND / OR SOLUBILITY AND METHOD OF MANUFACTURE | |
| JP4018664B2 (en) | 2003-04-30 | 2007-12-05 | 第一三共株式会社 | Stabilized solid preparation |
| DE10337198A1 (en) * | 2003-08-13 | 2005-03-17 | Degussa Ag | Carriers based on granules produced from pyrogenically prepared silicon dioxides |
| US8025899B2 (en) * | 2003-08-28 | 2011-09-27 | Abbott Laboratories | Solid pharmaceutical dosage form |
| JP2005075826A (en) | 2003-08-29 | 2005-03-24 | Boehringer Ingelheim Internatl Gmbh | Controlled release preparation comprising porous silica support |
| WO2005032525A1 (en) * | 2003-10-03 | 2005-04-14 | Lifecycle Pharma A/S | A method for preparing modified release pharmaceutical compositions |
| US20070014846A1 (en) * | 2003-10-10 | 2007-01-18 | Lifecycle Pharma A/S | Pharmaceutical compositions comprising fenofibrate and atorvastatin |
| EP1680091B1 (en) * | 2003-10-10 | 2017-05-31 | Veloxis Pharmaceuticals A/S | A solid dosage form comprising a fibrate |
| KR20060085682A (en) * | 2003-10-10 | 2006-07-27 | 라이프사이클 파마 에이/에스 | A solid dosage form comprising a fibrate and a statin |
| US20050096390A1 (en) * | 2003-10-10 | 2005-05-05 | Per Holm | Compositions comprising fenofibrate and pravastatin |
| US9173847B2 (en) * | 2003-10-10 | 2015-11-03 | Veloxis Pharmaceuticals A/S | Tablet comprising a fibrate |
| US20050096391A1 (en) * | 2003-10-10 | 2005-05-05 | Per Holm | Compositions comprising fenofibrate and rosuvastatin |
| US20050095287A1 (en) * | 2003-10-29 | 2005-05-05 | Matharu Amol S. | Fosinopril composition |
| WO2005084670A1 (en) * | 2004-03-01 | 2005-09-15 | Lek Pharmaceuticals D.D. | Pharmaceutical formulation |
| MY142989A (en) | 2004-03-10 | 2011-02-14 | Bayer Schering Pharma Ag | Stabilised supersaturated solids of lipophilic drugs |
| WO2005105040A2 (en) * | 2004-04-26 | 2005-11-10 | Micelle Products, Inc. | Water-soluble formulations of fat soluble vitamins and pharmaceutical agents and their applications |
| MY134672A (en) | 2004-05-20 | 2007-12-31 | Japan Tobacco Inc | Stable crystal of 4-oxoquinoline compound |
| WO2006000229A2 (en) | 2004-06-28 | 2006-01-05 | Lifecycle Pharma A/S | Porous tablets as carriers for liquid formulations |
| US20060009603A1 (en) * | 2004-07-09 | 2006-01-12 | David Young | Fibrillation-resistant polypropylene tape |
| AR045841A1 (en) | 2004-09-28 | 2005-11-16 | Richmond Sa Com Ind Y Financie | A SOLID PHARMACEUTICAL COMPOSITION THAT INCLUDES THE TIAZOLIL METHYL ESTER OF THE ACID [5S- (5R *, 8R *, 10R *, 11R *)] -10- HYDROXY-2-METHYL-5- (1-METHYTILE) -1- [2 - (1-METHYLE) -4-TIAZOLIL] -3,6-DIOXO-8,11-BIS (PHENYLMETIL) -2,4,7,12- TETRAAZATRIDECAN-13-OICO AND A PROCEDURE TO PREPARE IT. |
| TWI471145B (en) | 2005-06-13 | 2015-02-01 | Bristol Myers Squibb & Gilead Sciences Llc | Unitary pharmaceutical dosage form |
| TWI375560B (en) | 2005-06-13 | 2012-11-01 | Gilead Sciences Inc | Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same |
| US20070014854A1 (en) * | 2005-07-15 | 2007-01-18 | Ilan Zalit | Novel granulation process |
| JP2007039338A (en) | 2005-07-29 | 2007-02-15 | Hirofumi Takeuchi | Siliceous composite granule |
| US20080317852A1 (en) | 2005-12-14 | 2008-12-25 | Amar Lulla | Pharmaceutical Combination |
| BRPI0620578A2 (en) | 2005-12-27 | 2011-12-06 | Jubilant Organosys Ltd | pharmaceutical composition that dissolves in the mouth and process for the preparation thereof |
| KR101486590B1 (en) | 2006-01-05 | 2015-01-26 | 벨로시스 파마슈티컬스 에이/에스 | Disintegrating loadable tablets |
| EP1990062A1 (en) | 2006-02-20 | 2008-11-12 | ASAHI BREWERIES, Ltd. | Granules, tablets and method of producing the same |
| JP2009530382A (en) | 2006-03-23 | 2009-08-27 | シェーリング コーポレイション | Combinations of HCV protease inhibitors and CYP3A4 inhibitors and related treatment methods |
| ES2546378T3 (en) * | 2006-07-07 | 2015-09-23 | Gilead Sciences, Inc. | Modulators of pharmacokinetic properties of therapeutic agents |
| TW200815033A (en) * | 2006-08-10 | 2008-04-01 | Cipla Ltd | Antiretroviral solid oral composition |
| WO2008029417A2 (en) | 2006-09-04 | 2008-03-13 | Matrix Laboratories Limited | Pharmaceutical formulation for use in hiv therapy |
| US7749537B2 (en) * | 2006-12-04 | 2010-07-06 | Scolr Pharma, Inc. | Method of forming a tablet |
| EA019893B1 (en) * | 2007-02-23 | 2014-07-30 | Джилид Сайэнс, Инк. | Pharmaceutical composition and method for treating hiv infection |
| CN101743004A (en) | 2007-06-29 | 2010-06-16 | 吉里德科学公司 | Therapeutic compositions and the use thereof |
| SG182229A1 (en) | 2007-06-29 | 2012-07-30 | Gilead Sciences Inc | Therapeutic compositions and the use thereof |
| WO2009037449A1 (en) | 2007-09-18 | 2009-03-26 | Cipla Limited | Solid pharmaceutical compositions comprising one or more herpes virus inhibitors and one or more reverse transcriptase inhibitors |
| MX2010011963A (en) | 2008-05-02 | 2010-12-06 | Gilead Sciences Inc | The use of solid carrier particles to improve the processability of a pharmaceutical agent. |
| KR101738325B1 (en) | 2009-02-06 | 2017-05-19 | 길리애드 사이언시즈, 인코포레이티드 | Tablets for combination therapy |
| EP2238979A1 (en) | 2009-04-06 | 2010-10-13 | LEK Pharmaceuticals d.d. | Active pharmaceutical ingredient adsorbed on solid support |
| TW201728582A (en) | 2016-01-28 | 2017-08-16 | 基利科學股份有限公司 | Crystalline form |
-
2009
- 2009-05-01 MX MX2010011963A patent/MX2010011963A/en active IP Right Grant
- 2009-05-01 NZ NZ588978A patent/NZ588978A/en unknown
- 2009-05-01 CN CN200980115840XA patent/CN102123700A/en active Pending
- 2009-05-01 US US12/434,513 patent/US10039718B2/en active Active
- 2009-05-01 BR BRPI0911871A patent/BRPI0911871A8/en not_active IP Right Cessation
- 2009-05-01 AU AU2009242451A patent/AU2009242451C1/en active Active
- 2009-05-01 EP EP15184628.4A patent/EP3006032A1/en not_active Withdrawn
- 2009-05-01 EA EA201071173A patent/EA022950B1/en unknown
- 2009-05-01 DK DK09739981.0T patent/DK2296633T3/en active
- 2009-05-01 CN CN201510408376.0A patent/CN104940937A/en active Pending
- 2009-05-01 EA EA201591353A patent/EA201591353A1/en unknown
- 2009-05-01 CN CN201310447258.1A patent/CN103479584A/en active Pending
- 2009-05-01 CA CA2720856A patent/CA2720856C/en active Active
- 2009-05-01 EP EP09739981.0A patent/EP2296633B1/en not_active Revoked
- 2009-05-01 JP JP2011507697A patent/JP5722213B2/en active Active
- 2009-05-01 MX MX2014015438A patent/MX342377B/en unknown
- 2009-05-01 KR KR1020107026980A patent/KR101659971B1/en active IP Right Grant
- 2009-05-01 SG SG10201609006WA patent/SG10201609006WA/en unknown
- 2009-05-01 ES ES09739981.0T patent/ES2553897T3/en active Active
- 2009-05-01 KR KR1020167025826A patent/KR101784647B1/en active IP Right Grant
- 2009-05-01 SI SI200931286T patent/SI2296633T1/en unknown
- 2009-05-01 WO PCT/US2009/042607 patent/WO2009135179A2/en active Application Filing
- 2009-05-01 PL PL09739981T patent/PL2296633T3/en unknown
- 2009-05-01 SG SG2013033329A patent/SG190618A1/en unknown
- 2009-05-01 AP AP2010005429A patent/AP3089A/en active
- 2009-05-01 HU HUE09739981A patent/HUE026380T2/en unknown
- 2009-05-01 PT PT97399810T patent/PT2296633E/en unknown
-
2010
- 2010-10-11 IL IL208614A patent/IL208614A/en active IP Right Review Request
- 2010-10-28 CO CO10134187A patent/CO6321225A2/en not_active Application Discontinuation
- 2010-11-09 ZA ZA2010/08007A patent/ZA201008007B/en unknown
- 2010-11-26 EC EC2010010636A patent/ECSP10010636A/en unknown
-
2011
- 2011-08-02 HK HK11107966.2A patent/HK1153670A1/en unknown
-
2013
- 2013-10-22 JP JP2013218876A patent/JP5925171B2/en active Active
-
2014
- 2014-09-03 AU AU2014221210A patent/AU2014221210C1/en active Active
-
2015
- 2015-12-09 HR HRP20151357TT patent/HRP20151357T1/en unknown
- 2015-12-22 CY CY20151101168T patent/CY1117067T1/en unknown
-
2016
- 2016-03-30 HK HK16103674.9A patent/HK1215679A1/en unknown
- 2016-08-22 IL IL247417A patent/IL247417A0/en unknown
- 2016-10-28 AU AU2016250470A patent/AU2016250470A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2014221210A1 (en) | The use of solid carrier particles to improve the processability of a pharmaceutical agent | |
| IL247417A0 (en) | The use of solid carrier particles to improve the processability of a pharmaceutical agent | |
| EP2403852B8 (en) | 2-aminobenzimidazole-5-carboxamides as anti-inflammatory agents | |
| GB0710369D0 (en) | Improvements relating to perfume particles | |
| EP2999751B8 (en) | Anti-corrosive particles | |
| IL203051A (en) | Use of alpha-ketoglutarate for the preparation of medicaments | |
| IL196976A0 (en) | Use of azabicyclo hexane derivatives | |
| EP2268435A4 (en) | A process for the preparation of silver nano particles | |
| ZA201007610B (en) | Processes for the preparation of benzo-fused dioxin derivatives | |
| PL2143429T4 (en) | Use of cilastatin to reduce the nephrotoxicity of different compounds | |
| GB0623897D0 (en) | Pharmaceutical composition of memantine | |
| HK1222553A1 (en) | The use of solid carrier particles to improve the processability of a pharmaceutical agent | |
| SI2079472T1 (en) | High-purity large-scale preparation of stannsoporfin | |
| AU2014203754B2 (en) | High-purity large-scale preparation of stannsoporfin | |
| AU2007904492A0 (en) | Improvements to the Detection of Asbestos | |
| AU2009200375A1 (en) | Aquamiser "Aquapad" | |
| AU2009902395A0 (en) | Toddler's Half-Bath | |
| GB0701903D0 (en) | Proximity of particles | |
| AU2006907081A0 (en) | Improvement to Whitegoods | |
| AU2009905867A0 (en) | Pyranoindole compounds and uses thereof | |
| AU2007905796A0 (en) | Process for the preparation of graphene | |
| AU2010902506A0 (en) | Synaptai'd | |
| EP1821181B8 (en) | Mouse structure | |
| AU2008903802A0 (en) | Pharmaceutical Compound & Composition | |
| AU2009903930A0 (en) | Novel compounds and their uses |